Switch theme
Sign up to access all valuation multiples
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to global preclinical research and development communities. It specializes in developing animal models using cutting edge gene-editing technologies with a large collection of cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice.
2017
n/a
LTM Revenue $102M
LTM EBITDA $29.2M
$579M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GemPharmatech has a last 12-month revenue (LTM) of $102M and a last 12-month EBITDA of $29.2M.
In the most recent fiscal year, GemPharmatech achieved revenue of $95.3M and an EBITDA of $28.9M.
GemPharmatech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GemPharmatech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $102M | XXX | $95.3M | XXX | XXX | XXX |
| Gross Profit | $63.2M | XXX | $59.1M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $29.2M | XXX | $28.9M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $18.1M | XXX | $17.0M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $16.7M | XXX | $15.2M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, GemPharmatech's stock price is CNY 12 (or $2).
GemPharmatech has current market cap of CNY 5.1B (or $703M), and EV of CNY 4.2B (or $579M).
See GemPharmatech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $579M | $703M | XXX | XXX | XXX | XXX | $0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, GemPharmatech has market cap of $703M and EV of $579M.
GemPharmatech's trades at 6.1x EV/Revenue multiple, and 20.0x EV/EBITDA.
Equity research analysts estimate GemPharmatech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GemPharmatech has a P/E ratio of 42.2x.
See valuation multiples for GemPharmatech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $703M | XXX | $703M | XXX | XXX | XXX |
| EV (current) | $579M | XXX | $579M | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 19.9x | XXX | 20.0x | XXX | XXX | XXX |
| EV/EBIT | 32.0x | XXX | 34.1x | XXX | XXX | XXX |
| EV/Gross Profit | 9.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 42.2x | XXX | 46.1x | XXX | XXX | XXX |
| EV/FCF | 34.7x | XXX | -178.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGemPharmatech's last 12 month revenue growth is 15%
GemPharmatech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
GemPharmatech's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GemPharmatech's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GemPharmatech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 50% | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 66% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GemPharmatech acquired XXX companies to date.
Last acquisition by GemPharmatech was XXXXXXXX, XXXXX XXXXX XXXXXX . GemPharmatech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was GemPharmatech founded? | GemPharmatech was founded in 2017. |
| Where is GemPharmatech headquartered? | GemPharmatech is headquartered in China. |
| Is GemPharmatech publicy listed? | Yes, GemPharmatech is a public company listed on SHG. |
| What is the stock symbol of GemPharmatech? | GemPharmatech trades under 688046 ticker. |
| When did GemPharmatech go public? | GemPharmatech went public in 2022. |
| Who are competitors of GemPharmatech? | Similar companies to GemPharmatech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of GemPharmatech? | GemPharmatech's current market cap is $703M |
| What is the current revenue of GemPharmatech? | GemPharmatech's last 12 months revenue is $102M. |
| What is the current revenue growth of GemPharmatech? | GemPharmatech revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of GemPharmatech? | Current revenue multiple of GemPharmatech is 5.7x. |
| Is GemPharmatech profitable? | Yes, GemPharmatech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GemPharmatech? | GemPharmatech's last 12 months EBITDA is $29.2M. |
| What is GemPharmatech's EBITDA margin? | GemPharmatech's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of GemPharmatech? | Current EBITDA multiple of GemPharmatech is 19.9x. |
| What is the current FCF of GemPharmatech? | GemPharmatech's last 12 months FCF is $16.7M. |
| What is GemPharmatech's FCF margin? | GemPharmatech's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of GemPharmatech? | Current FCF multiple of GemPharmatech is 34.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
